January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
October 2025 in “CRC Press eBooks” November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
23 citations
,
September 2020 in “BMC Cancer” 5α-reductase inhibitors may lower the risk of death from bladder cancer.
1 citations
,
February 2022 in “The Journal of Urology” Certain drugs like Dutasteride and Finasteride might help fight SARS-CoV-2 by increasing levels of a steroid called DHEA, which can protect the heart and increase nitric oxide to counteract the virus.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
45 citations
,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
3 citations
,
March 2018 in “European Urology Supplements” Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
1 citations
,
November 2024 in “Archives of Dermatological Research”
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
6 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.